Celldex Therapeutics, Inc.CLDXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +110.35% | -71.56% | +345.51% | -70.78% | -100.00% |
| Gross Profit Growth | +325.47% | +0.00% | +0.00% | -57.08% | -100.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +40.27% | +27.53% | +12.76% | +0.56% | +0.19% |
| Weighted Average Shares Diluted Growth | +40.27% | +27.53% | +12.76% | +0.56% | +0.19% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +238.10% | -84.54% | -60.16% | -94.13% | -89.44% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +193.72% | +70.17% | -14.89% | -18.12% | -21.23% |
| Book Value per Share Growth | +127.09% | +36.48% | -25.66% | -19.90% | -24.01% |
| Debt Growth | +8.47% | +50.00% | +62.16% | +27.09% | -15.10% |
| R&D Expense Growth | -99.99% | +51.58% | +70.35% | +39.36% | +2097600.00% |
| SG&A Expenses Growth | +22.30% | +16.20% | +18.86% | +13.84% | +6.29% |